Literature DB >> 28161150

Mechanisms of action of intravenous immunoglobulin.

Benjamin Chaigne1, Luc Mouthon2.   

Abstract

Taking advantage of the "World Apheresis Association/Société Française d'Hémaphérèse" meeting held in Paris in April 2016, this article reviews the current knowledge on the mechanisms of action of intravenous immunoglobulins. Immunoglobulins are a plasma-derived drug, which have been initially used as a replacement therapy for patients with antibody deficiency. Since 1980 they have also been used for their anti-inflammatory and immunomodulating efficacy in auto-immune diseases. Herein, we review the requirements for their production and composition before giving a specific attention to their mechanisms of action including substitution and immunomodulation.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Auto-immune diseases; Immunomodulation; Intravenous immunoglobulins; Substitution

Mesh:

Substances:

Year:  2016        PMID: 28161150     DOI: 10.1016/j.transci.2016.12.017

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  29 in total

Review 1.  Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management.

Authors:  Adena Zadourian; Taylor A Doherty; Iwona Swiatkiewicz; Pam R Taub
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  Immune cell diversity contributes to the pathogenesis of myocarditis.

Authors:  Xiumeng Hua; Jiangping Song
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 3.  Immunotherapy in Narcolepsy.

Authors:  Maria Pia Giannoccaro; Giombattista Sallemi; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Curr Treat Options Neurol       Date:  2020-01-30       Impact factor: 3.598

4.  Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity.

Authors:  Thomas Grüter; Anthonina Ott; Wolfgang Meyer; Sven Jarius; Markus Kinner; Jeremias Motte; Kalliopi Pitarokoili; Ralf Gold; Lars Komorowski; Ilya Ayzenberg
Journal:  J Neurol       Date:  2019-11-14       Impact factor: 4.849

Review 5.  Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19.

Authors:  Xi Hu; Chen Jia; Jianyong Wu; Jian Zhang; Zhijie Jiang; Kuifen Ma
Journal:  Front Cell Infect Microbiol       Date:  2022-06-20       Impact factor: 6.073

6.  A Phase I/IIa Trial of Intravenous Immunoglobulin Following Portoenterostomy in Biliary Atresia.

Authors:  Cara L Mack; Cathie Spino; Estella M Alonso; Jorge A Bezerra; Jeffrey Moore; Catherine Goodhue; Vicky L Ng; Saul J Karpen; Veena Venkat; Kathleen M Loomes; Kasper Wang; Averell H Sherker; John C Magee; Ronald J Sokol
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-04       Impact factor: 2.839

7.  Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program.

Authors:  Benjamin A Derman; Zachary Schlei; Sandeep Parsad; Kathleen Mullane; Randall W Knoebel
Journal:  JCO Oncol Pract       Date:  2020-08-21

8.  IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans.

Authors:  J Bayry; A Aouba; A Nguyen; Y Repesse; M Ebbo; Y Allenbach; O Benveniste; J M Vallat; L Magy; S Deshayes; G Maigné; H de Boysson; A Karnam; S Delignat; S Lacroix-Desmazes
Journal:  Clin Exp Immunol       Date:  2021-02-22       Impact factor: 4.330

9.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

10.  Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.

Authors:  Vera Bril; Michael Benatar; Henning Andersen; John Vissing; Melissa Brock; Bernhard Greve; Peter Kiessling; Franz Woltering; Laura Griffin; Peter Van den Bergh
Journal:  Neurology       Date:  2020-11-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.